Who are Atacand's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Giapreza, Benicar, Teveten, Avapro, Avapro, Diovan.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/candesartan-cilexetil.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Atacand — Competitive Intelligence Brief

Atacand (CANDESARTAN CILEXETIL) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Angiotensin 2 Receptor Blocker. Area: Metabolic.

marketed Angiotensin 2 Receptor Blocker Type-1 angiotensin II receptor Metabolic Small molecule Live · refreshed every 30 min

Target snapshot

Atacand (CANDESARTAN CILEXETIL) — ANI Pharmaceuticals. Atacand blocks the action of angiotensin II, a hormone that constricts blood vessels, to lower blood pressure and improve heart function.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Atacand TARGET	CANDESARTAN CILEXETIL	ANI Pharmaceuticals	marketed	Angiotensin 2 Receptor Blocker	Type-1 angiotensin II receptor	1998-01-01
Giapreza	ANGIOTENSIN II	La Jolla Pharma	marketed	Vasoconstrictor [EPC]	Type-2 angiotensin II receptor, Type-1 angiotensin II receptor, Type-1 angiotensin II receptor	2017-01-01
Benicar	OLMESARTAN MEDOXOMIL	Cosette	marketed	Thiazide Diuretic [EPC]	Type-1 angiotensin II receptor	2002-01-01
Teveten	EPROSARTAN	AbbVie	marketed	Angiotensin 2 Receptor Blocker	Type-1 angiotensin II receptor	1997-01-01
Avapro	IRBESARTAN HYDROCHLORIDE	Sanofi	marketed	Angiotensin 2 Receptor Blocker [EPC]	Type-1 angiotensin II receptor	1997-01-01
Avapro	IRBESARTAN	Sanofi	marketed	Angiotensin 2 Receptor Blocker [EPC]	Type-1 angiotensin II receptor	1997-01-01
Diovan	VALSARTAN	Novartis	marketed	Angiotensin 2 Receptor Blocker [EPC]	Type-1 angiotensin II receptor	1996-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Angiotensin 2 Receptor Blocker class)

ANI Pharmaceuticals · 1 drug in this class
AbbVie · 1 drug in this class
Arbor Pharms Ireland · 1 drug in this class
Merck & Co. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Atacand — Competitive Intelligence Brief. https://druglandscape.com/ci/candesartan-cilexetil. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab